دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Table of Contents
doi : 10.1016/S0923-7534(23)05004-4
Volume 34, Issue 12, December 2023, Pages i-ii
Annals of Oncology 2018-2023
F. Andre*, on behalf of the Editorial Board
doi : 10.1016/j.annonc.2023.08.019
Volume 34, Issue 12, December 2023, Pages 1069-1070
The ELAINE trials and the future of personalized therapy for hormone-receptor positive metastatic breast cancer
Seth A. Wander*
doi : 10.1016/j.annonc.2023.10.792
Volume 34, Issue 12, December 2023, Pages 1071-1073
Is more of a good thing still a good thing? PARP inhibitor retreatment in high-grade ovarian carcinoma
I. A. McNeish 1 * & B. J. Monk
doi : 10.1016/j.annonc.2023.08.014
Volume 34, Issue 12, December 2023, Pages 1074-1076
Favorable long-term Health Related Quality of Life in cured survivors of testicular cancer management. So, what now?
A. D’Souza MD 1,y, J. King MD 2,y, L. Nappi MD PhD 3 , S. Daneshmand 4 , C. Nichols MD 3,5 & C. Kollmannsberger MD
doi : 10.1016/j.annonc.2023.11.001
Volume 34, Issue 12, December 2023, Pages 1077-1079
Circulating tumour DNA for detection of minimal residual disease in head and neck squamous cell carcinoma: A new hope
W. K. Jacky Lam 1,2,3,4,5 *, Guannan Kang 1,2,3 & W. S. Winsome Wong
doi : 10.1016/j.annonc.2023.10.693
Volume 34, Issue 12, December 2023, Pages 1080-1081
Changing cancer representations toward comprehensive portraits to empower patients in their care journey
M. A. Franzoi 1 *, A. Bayle2,3 & I. Vaz-Luis
doi : 10.1016/j.annonc.2023.09.3117
Volume 34, Issue 12, December 2023, Pages 1082-1087
Moving toward precision oncology centers V2.0
S. Dogan1 , P.-H. Cournède 2 , E. Solary 3,4,5 , J.-M. Heard 1 , M. Aldea 1,6 , T. Conroy7,8 , C. Robert1,5,6 & F. André
doi : 10.1016/j.annonc.2023.09.3115
Volume 34, Issue 12, December 2023, Pages 1088-1089
WGS/WES-RNAseq compared to targeted NGS in oncology: is there something to unlock?
M. Aldea 1,2,3 , D. Vasseur 3,4 , A. Italiano3,5 & S. I. Nikolaev 6 *
doi : 10.1016/j.annonc.2023.09.3118
Volume 34, Issue 12, December 2023, Pages 1090-1093
Time to treat the climate and nature crisis as one indivisible global health emergency☆
K. Abbasi1 , P. Ali2 , V. Barbour 3 , T. Benfield 4 , K. Bibbins-Domingo 5 , S. Hancocks 6 , R. Horton 7 , L. Laybourn-Langton 8 , R. Mash 9 , P. Sahni 10 , W. M. Sharief 11 , P. Yonga12 & C. Zielinski
doi : 10.1016/j.annonc.2023.10.692
Volume 34, Issue 12, December 2023, Pages 1094-1096
ESMO Guidance for Reporting Oncology real-World evidence (GROW)
L. Castelo-Branco1, A. Pellat 2,3y, D. Martins-Branco 1,4y, A. Valachis 5y, J. W. G. Derksen 6y, K. P. M. Suijkerbuijk7 , U. Dafni8,9 , T. Dellaporta 9 , A. Vogel10,11,12 , A. Prelaj 13,14 , R. H. H. Groenwold 15 , H. Martins 16 , R. Stahel17 , J. Bliss 18 , J. Kather 19,20 , N. Ribelles21 , F. Perrone22 , P. S. Hall 23 , R. Dienstmann24,25 , C. M. Booth26,27 , G. Pentheroudakis 1z, S. Delaloge28z & M. Koopman
doi : 10.1016/j.annonc.2023.10.001
Volume 34, Issue 12, December 2023, Pages 1097-1112
The impact of genomic context on outcomes of solid cancer patients treated with genotype-matched targeted therapies: a comprehensive review
T. Fulton-Ward1 & G. Middleton
doi : 10.1016/j.annonc.2023.10.124
Volume 34, Issue 12, December 2023, Pages 1113-1130
Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2− breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2
S. Damodaran1, C. C. O’Sullivan 2 , A. Elkhanany3 , I. C. Anderson4 , M. Barve 5 , S. Blau 6 , M. A. Cherian7 , J. A. Peguero8 , M. P. Goetz2 , P. V. Plourde9 , D. J. Portman9 & H. C. F. Moore
doi : 10.1016/j.annonc.2023.09.3103
Volume 34, Issue 12, December 2023, Pages 1131-1140
Lasofoxifene versus fulvestrant for ER+/HER2− metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial
M. P. Goetz1, N. A. Bagegni2 , G. Batist 3 , A. Brufsky4 , M. A. Cristofanilli 5 , S. Damodaran6 , B. R. Daniel 7 , G. F. Fleming8 , W. J. Gradishar 9 , S. L. Graff 10 , M. T. Grosse Perdekamp11 , E. Hamilton 12 , S. Lavasani 13 , A. Moreno-Aspitia 14 , T. O’Connor15 , T. J. Pluard 16 , H. S. Rugo17 , S. L. Sammons18 , L. S. Schwartzberg 19 , D. G. Stover 20 , G. A. Vidal21 , G. Wang 22 , E. Warner23 , R. Yerushalmi 24 , P. V. Plourde25 , D. J. Portman 25 & E. N. Gal-Yam 26
doi : 10.1016/j.annonc.2023.09.3104
Volume 34, Issue 12, December 2023, Pages 1141-1151
Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial
E. Pujade-Lauraine 1,2, F. Selle 2,3 , G. Scambia 4,5 , B. Asselain 1,2 , F. Marmé 6,7 , K. Lindemann 8,9,10 , N. Colombo 11,12 , R. M?dry 13,14 , R. Glasspool 15,16,17 , I. Vergote 18,19 , J. Korach 20,21 , S. Lheureux 22,23 , C. Dubot 2,24 , A. Oaknin 25,26 , C. Zamagni 5,27 , F. Heitz 28,29,30,31 , L. Gladieff 2,32 , M. J. Rubio-Pérez 26,33 , P. Scollo 5,34,35 , C. Blakeley 36y, B. Shaw 36 , I. Ray-Coquard2,37 & A. Redondo 26,38 , on behalf of the OReO/ENGOT-ov38 investigators
doi : 10.1016/j.annonc.2023.09.3110
Volume 34, Issue 12, December 2023, Pages 1152-1164
Adverse health outcomes and global quality of life in long-term testicular cancer survivors: a longitudinal 30-year perspective
S. D. Foss? 1,2, H. S. Haugnes 3,4 , A. A. Dahl 1 , C. E. Kiserud1 , A. Foss? 1 , J. Skalleberg 5 & T. ?. Myklebust
doi : 10.1016/j.annonc.2023.09.3101
Volume 34, Issue 12, December 2023, Pages 1165-1174
Tumor-agnostic plasma assay for circulating tumor DNA detects minimal residual disease and predicts outcome in locally advanced squamous cell carcinoma of the head and neck
N. Honoré1,2 , C. van Marcke 1,2 , R. Galot 1,2 , R. Helaers 3 , J. Ambroise 4 , A. van Maanen5 , A. Mendola1 , H. Dahou 1 , E. Marbaix6 , P. Van Eeckhout 6 , E. Longton 7 , M. Magremanne1,8 , S. Schmitz 1,9 , N. Limaye 10 & J.-P. Machiels
doi : 10.1016/j.annonc.2023.09.3102
Volume 34, Issue 12, December 2023, Pages 1175-1186
High accuracy of a blood ctDNA-based multimodal test to detect colorectal cancer
X. Bessa1y, J. Vidal2y, J. C. Balboa1 , C. M?rquez 1 , S. Duenwald3 , Y. He 3 , V. Raymond3 , I. Faull 3 , A. Bur?n4,5 , C. ?lvarez-Urturi 1 , X. Castells4,5 , B. Bellosillo 6 & C. Montagut
doi : 10.1016/j.annonc.2023.09.3113
Volume 34, Issue 12, December 2023, Pages 1187-1193
Diversity in clinical trials in Europe and the USA: a review of a pharmaceutical company’s data collection, reporting, and interpretation of race and ethnicity
N. M. Candelario, J. Major, B. Dreyfus, D. Sattler, D. Paulucci, S. Misra, M. Micsinai & L. Kuri*
doi : 10.1016/j.annonc.2023.09.3107
Volume 34, Issue 12, December 2023, Pages 1194-1197
VP5-2023: Primary results from BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030), a randomised phase III trial of first-line atezolizumab (atezo) combined with a platinum doublet and bevacizumab (bev) for metastatic (stage IVB), persistent or recurrent cervical cancer (R/M CC)
A. Oaknin1, L. Gladieff 2 , J. Martinez-Garcia3 , G. Villacampa 4 , M. Takekuma5 , U. F. F. De Giorgi6 , K. Lindemann 7 , L. Woelber 8 , N. Colombo 9 , L. R. Duska10 , A. Leary 11 , A. Godoy Ortiz 12 , S. Nishio 13 , A. Angelergues 14 , M. J. Rubio Perez 15 , L. Fari?as Madrid 16 , S. Yamaguchi 17 , D. Lorusso 18 , V. D’Hondt 19 & L. Randall
doi : 10.1016/j.annonc.2023.10.694
Volume 34, Issue 12, December 2023, Pages 1198-1200
Retraction notice to “CN5 - Examination of mobile applications on breast cancer�: [Annals of Oncology 30S5 (2019) v817]
A. Aydin1 & A. Gursoy
doi : 10.1016/j.annonc.2023.07.009
Volume 34, Issue 12, December 2023, Page 1201
Retraction notice to “CN17 - Using mobile-based health care applications outcomes: Mini systematic review�: [Annals of Oncology 30S5 (2019) v820]
A. Aydin1 & A. Gursoy
doi : 10.1016/j.annonc.2023.07.008
Volume 34, Issue 12, December 2023, Page 1202
Retraction notice to “CN104 - How should the symptoms be managed after breast cancer surgery? An example of mobile app�: [Annals of Oncology 30S5 (2019) v845]
A. Aydin1 & A. Gursoy
doi : 10.1016/j.annonc.2023.07.007
Volume 34, Issue 12, December 2023, Page 1203
